| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
103,197 |
77,945 |
$4.39M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
110,332 |
82,015 |
$2.72M |
| 96138 |
|
71,779 |
53,932 |
$1.29M |
| L0648 |
Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
2,485 |
1,996 |
$574K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
34,270 |
30,418 |
$487K |
| 96127 |
|
156,330 |
99,662 |
$476K |
| 92548 |
|
8,424 |
7,172 |
$473K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
6,599 |
5,407 |
$422K |
| 62323 |
|
4,348 |
3,225 |
$405K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
12,773 |
5,478 |
$301K |
| 80348 |
|
29,411 |
26,939 |
$287K |
| 80365 |
|
32,377 |
29,499 |
$263K |
| 80354 |
|
29,399 |
26,925 |
$234K |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
14,332 |
5,272 |
$216K |
| 98942 |
|
8,402 |
3,313 |
$184K |
| 98980 |
|
5,938 |
4,301 |
$180K |
| 64635 |
|
1,211 |
873 |
$179K |
| 80361 |
|
32,405 |
29,533 |
$179K |
| 80362 |
|
29,421 |
26,924 |
$178K |
| 80369 |
|
32,407 |
29,517 |
$175K |
| 64493 |
|
3,561 |
2,302 |
$166K |
| 80346 |
|
32,399 |
29,526 |
$164K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
23,581 |
17,023 |
$160K |
| 62321 |
|
1,472 |
1,137 |
$158K |
| 80375 |
|
29,391 |
26,921 |
$140K |
| 98981 |
|
5,354 |
3,930 |
$138K |
| 64483 |
|
1,675 |
1,183 |
$131K |
| 80324 |
|
29,424 |
26,943 |
$130K |
| 96160 |
|
103,222 |
77,978 |
$126K |
| 80358 |
|
24,645 |
22,636 |
$124K |
| A4595 |
Electrical stimulator supplies, 2 lead, per month, (e.g., tens, nmes) |
6,607 |
5,816 |
$117K |
| 80321 |
|
32,414 |
29,544 |
$114K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
1,315 |
1,263 |
$110K |
| 80349 |
|
29,415 |
26,944 |
$106K |
| 27096 |
|
1,467 |
968 |
$103K |
| 80373 |
|
32,399 |
29,514 |
$101K |
| 80323 |
|
24,649 |
22,626 |
$98K |
| 99386 |
|
891 |
847 |
$96K |
| 20610 |
|
3,976 |
2,870 |
$95K |
| 77002 |
|
3,980 |
2,924 |
$94K |
| 64494 |
|
3,453 |
2,240 |
$92K |
| 80356 |
|
29,335 |
26,868 |
$89K |
| 80372 |
|
29,376 |
26,910 |
$89K |
| 64636 |
|
1,166 |
837 |
$84K |
| 80355 |
|
32,384 |
29,503 |
$78K |
| E0730 |
Transcutaneous electrical nerve stimulation (tens) device, four or more leads, for multiple nerve stimulation |
3,317 |
2,683 |
$70K |
| 80338 |
|
24,631 |
22,622 |
$67K |
| 80368 |
|
32,376 |
29,490 |
$67K |
| 80360 |
|
29,387 |
26,897 |
$59K |
| L1832 |
Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
350 |
216 |
$49K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
4,283 |
3,455 |
$49K |
| 80357 |
|
24,631 |
22,619 |
$49K |
| 80333 |
|
24,641 |
22,627 |
$49K |
| 99385 |
|
548 |
502 |
$49K |
| L0631 |
Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
188 |
152 |
$48K |
| 98977 |
|
1,269 |
838 |
$48K |
| 64484 |
|
1,124 |
872 |
$44K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
630 |
599 |
$40K |
| 64495 |
|
1,610 |
1,113 |
$34K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
5,167 |
4,299 |
$34K |
| 98940 |
|
3,145 |
1,379 |
$34K |
| 62370 |
|
957 |
643 |
$25K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
3,074 |
1,424 |
$17K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
4,859 |
3,338 |
$16K |
| 99457 |
|
795 |
440 |
$16K |
| L2397 |
Addition to lower extremity orthosis, suspension sleeve |
354 |
220 |
$14K |
| 97032 |
|
1,810 |
1,031 |
$13K |
| L2810 |
Addition to lower extremity orthosis, knee control, condylar pad |
346 |
210 |
$11K |
| 99454 |
|
295 |
127 |
$11K |
| 64490 |
|
211 |
132 |
$11K |
| J3490 |
Unclassified drugs |
11,944 |
8,806 |
$11K |
| L1843 |
Knee orthosis, single upright, thigh and calf, with adjustable flexion and extension joint (unicentric or polycentric), medial-lateral and rotation control, with or without varus/valgus adjustment, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
78 |
49 |
$10K |
| 97014 |
|
1,438 |
609 |
$9K |
| 20553 |
|
517 |
414 |
$9K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
337 |
292 |
$7K |
| 98975 |
|
684 |
575 |
$6K |
| 64491 |
|
209 |
131 |
$6K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
451 |
183 |
$5K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
9,165 |
7,118 |
$5K |
| 99458 |
|
562 |
269 |
$4K |
| 99422 |
|
224 |
167 |
$4K |
| L1833 |
Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated, off-the shelf |
14 |
12 |
$3K |
| 64492 |
|
90 |
55 |
$3K |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
154 |
138 |
$2K |
| 97750 |
|
225 |
158 |
$2K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
15,286 |
11,201 |
$2K |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
83 |
82 |
$2K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
224 |
157 |
$2K |
| 99442 |
|
48 |
32 |
$2K |
| 98970 |
|
371 |
300 |
$2K |
| 97012 |
|
198 |
101 |
$2K |
| 99421 |
|
168 |
134 |
$1K |
| 99453 |
|
159 |
134 |
$1K |
| 98976 |
|
41 |
14 |
$1K |
| 92546 |
|
29 |
12 |
$1K |
| 97010 |
|
1,215 |
513 |
$1K |
| 98971 |
|
121 |
103 |
$1K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
428 |
286 |
$1K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
195 |
148 |
$453.71 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
15 |
13 |
$416.64 |
| 92537 |
|
14 |
12 |
$381.96 |
| 97535 |
Self-care/home management training, each 15 minutes |
19 |
17 |
$289.83 |
| 99443 |
|
31 |
20 |
$287.32 |
| 96120 |
|
89 |
77 |
$144.30 |
| 80305 |
|
3,720 |
2,006 |
$115.52 |
| 96103 |
|
121 |
79 |
$28.55 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
537 |
294 |
$0.04 |
| 97039 |
|
166 |
62 |
$0.00 |
| 99024 |
|
155 |
137 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
82 |
76 |
$0.00 |
| 99406 |
|
105 |
79 |
$0.00 |
| 98943 |
|
40 |
12 |
$0.00 |